App-based investigation of patient-reported outcomes in TYSABRI therapy

• Conditions: G35; Multiple sclerosis

• Registration Number: DRKS00024387
• Lead Sponsor: Medizin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-15
• Study Completion: 2023-04-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

relapsing remitting multiple sclerosis

Exclusion Criteria

progressve multiple scleroses and patients without a therapy with natalizumab

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quality of life, fatigue and cognition during natalizumab therapy

Secondary Outcome Measures

Name	Time	Method
Parameter change during 12 months